Fate Therapeutics Company Profile (NASDAQ:FATE)

Analyst Ratings

Consensus Ratings for Fate Therapeutics (NASDAQ:FATE) (?)
Ratings Breakdown: 7 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.00 (311.76% upside)

Analysts' Ratings History for Fate Therapeutics (NASDAQ:FATE)
Show:
DateFirmActionRatingPrice TargetActions
6/21/2016BMO Capital MarketsReiterated RatingOutperform$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/21/2016Leerink SwannReiterated RatingOutperform$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/7/2016HC WainwrightReiterated RatingBuy$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/7/2015WedbushReiterated RatingOutperform$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2015Cowen and CompanyReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/6/2015Raymond James Financial Inc.Initiated CoverageOutperform$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Fate Therapeutics (NASDAQ:FATE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/9/2016Q116($0.25)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q415($0.27)($0.26)$1.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.30)($0.24)$1.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.39)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.37)($0.38)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.31)($0.30)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2014($0.29)($0.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214($0.37)($0.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.33)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2014Q413($0.27)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2013Q3($0.32)($4.81)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Fate Therapeutics (NASDAQ:FATE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.31)($0.27)($0.29)
Q2 20162($0.35)($0.33)($0.34)
Q3 20163($0.36)($0.33)($0.35)
Q4 20163($0.36)($0.24)($0.31)
Q1 20171($0.39)($0.39)($0.39)
Q2 20171($0.41)($0.41)($0.41)
Q3 20171($0.43)($0.43)($0.43)
Q4 20171($0.31)($0.31)($0.31)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Fate Therapeutics (NASDAQ:FATE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Fate Therapeutics (NASDAQ:FATE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/12/2014Peter D FlynnInsiderSell6,488$7.00$45,416.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2014Peter D FlynnInsiderSell3,305$7.00$23,135.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Peter D FlynnInsiderSell9,793$7.07$69,236.51View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2014Peter D FlynnInsiderSell5,889$8.00$47,112.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2014Christian WeyerInsiderSell10,000$9.02$90,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014J Scott WolchkoInsiderSell20,000$9.64$192,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/31/2014Daniel D ShoemakerCTOSell8,653$9.86$85,318.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/4/2013John MendleinDirectorBuy16,667$6.00$100,002.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/4/2013Venture Fund Vi Lp ArchMajor ShareholderBuy833,333$6.00$4,999,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Fate Therapeutics (NASDAQ:FATE)
DateHeadline
07/23/16 08:02 AMIncreased Volatility Noted on Shares of: Fate Therapeutics, Inc. (NASDAQ:FATE) - Engelwood Daily
07/23/16 08:02 AMEquity Roundup: Stock Performance Focus on Fate Therapeutics, Inc. (NASDAQ:FATE) - Press Telegraph
07/22/16 05:32 AMInvestor Update: Earnings and Target Price Recap on Fate Therapeutics, Inc. (NASDAQ:FATE) - Press Telegraph
07/21/16 07:30 AMHochman Cole Investment Advisors Lowers stake in Fate Therapeutics Inc (FATE) - TheFounders Daily
07/20/16 05:17 PMIncreased Stock Volatility Watch: Fate Therapeutics, Inc. (NASDAQ:FATE) - Engelwood Daily
07/20/16 05:17 PMFate Therapeutics, Inc. (NASDAQ:FATE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 05:17 PMFate Therapeutics Inc Stock Technicals Hit Weakness - CML News
07/20/16 05:28 AMStock Moving Lower for the Month; Investor Update on Fate Therapeutics, Inc. (NASDAQ:FATE) - Engelwood Daily
07/19/16 04:04 PMHC Stocks Newsbeat: Perrigo Company plc Ordinary Shares (NYSE:PRGO), Fate Therapeutics Inc (NASDAQ:FATE) - share market updates (press release)
07/19/16 10:05 AMStocks to Watch: Fate Therapeutics, Inc. (NASDAQ:FATE), The Coca-Cola Company (NYSE:KO), Lam Research ... - KC Register
07/19/16 10:05 AMFate Therapeutics, Inc. (NASDAQ:FATE) Wall Street Analyst Recommendation Outlook - TGP
07/16/16 07:23 AMShares Experiencing a Downtrend: Fate Therapeutics, Inc. (NASDAQ:FATE) - TGP
07/16/16 07:23 AMWere Analysts Bullish Fate Therapeutics Inc (NASDAQ:FATE) This Week? - Press Telegraph
07/14/16 09:19 PMRegenerative Medicine Market Segments and Key Trends 2016-2026
07/14/16 04:04 PMFate Therapeutics Inc (NASDAQ:FATE) Institutional Investor Positioning - Consumer Eagle
07/13/16 04:18 PMFate Therapeutics, Inc. (NASDAQ:FATE) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/11/16 03:58 PMWall Street Ratings and Target Price Views on Fate Therapeutics, Inc. (NASDAQ:FATE) - Telanagana Press
07/11/16 03:58 PMFate Therapeutics Inc Stock Momentum at Critical Inflection Point - CML News
07/10/16 03:43 PMFate Therapeutics Incorporated (NASDAQ:FATE) Shorted Shares Decreased By 8.49% - Engelwood Daily
07/09/16 07:25 AMAre Analysts Bullish Fate Therapeutics Inc (NASDAQ:FATE) After Last Week? - Press Telegraph
07/06/16 09:47 PMShare Volatility in Focus: Fate Therapeutics, Inc. (NASDAQ:FATE) - Engelwood Daily
07/06/16 09:47 PMCan Fate Therapeutics, Inc. (NASDAQ:FATE) Improve on the Earnings Front? - Engelwood Daily
07/05/16 03:50 PMCisco Systems, Inc. (NASDAQ:CSCO) Rose 0.38%: Fate Therapeutics, Inc. (NASDAQ:FATE), Adamas Pharmaceuticals ... - KC Register
07/04/16 08:47 AMResearch report explores the market analysis on stem cell - types, technologies and therapeutics
07/03/16 08:31 AMCompany Stock Lower on the Week Fate Therapeutics, Inc. (NASDAQ:FATE) - Engelwood Daily
07/01/16 03:57 PMShares Headed Up in Session: Fate Therapeutics, Inc. (NASDAQ:FATE) - Telanagana Press
07/01/16 03:57 PMWill Fate Therapeutics, Inc. (NASDAQ:FATE) Surprise This Quarter? - Investor Newswire
06/30/16 04:14 PMFate Therapeutics, Inc. - Product Pipeline Review - 2016 - New Market Research Report
06/30/16 05:56 AMWatching Stock Volatility for: Fate Therapeutics, Inc. (NASDAQ:FATE) - Engelwood Daily
06/28/16 03:55 PMCovering the Bases on Fate Therapeutics, Inc. (NASDAQ:FATE): Where is the Stock Going? - Press Telegraph
06/28/16 03:55 PMCheck on Share Volatility: Fate Therapeutics, Inc. (NASDAQ:FATE) - Engelwood Daily
06/27/16 03:54 PMStock Volatility in Review: Fate Therapeutics, Inc. (NASDAQ:FATE) - Engelwood Daily
06/27/16 08:26 AMFate Therapeutics Incorporated (NASDAQ:FATE) Short Interest Decreased By 8.49% - Press Telegraph
06/27/16 08:26 AMNext Weeks Broker Price Targets For Fate Therapeutics, Inc. (FATE) - Fiscal Standard
06/27/16 08:26 AMLarge Outflow of Money Witnessed in Fate Therapeutics - Trade Calls
06/24/16 04:01 PMAre Analysts Bullish Fate Therapeutics Inc (NASDAQ:FATE) After Last Week? - Engelwood Daily
06/22/16 04:06 PMFate Therapeutics (NASDAQ:FATE) Analyst Rating Consensus - TheFounders Daily
06/21/16 03:45 PMUS FDA grants fast track designation to Fate Therapeutics' ProTmune
06/21/16 03:45 PMFate Therapeutics (FATE) Boosted with FDA Fast-Track Designation
06/21/16 08:37 AMLpath, Inc. (NASDAQ:LPTN) & Fate Therapeutics (NASDAQ:FATE) Healthcare Investor's Alert - Wall Street 24
06/21/16 08:37 AMHC Stocks in Top Row: Perrigo Company plc (NYSE:PRGO), Fate Therapeutics Inc (NASDAQ:FATE) - share market updates (press release)
06/21/16 08:37 AMWhy muscled up? - Lpath, Inc. (NASDAQ:LPTN), Fate Therapeutics Inc (NASDAQ:FATE), Macrocure Ltd (NASDAQ ... - Street Register
06/21/16 07:25 AMFate Therapeutics (FATE) Catches Eye: Stock Jumps 19.1% -
06/20/16 03:49 PMFate Therapeutics destined to rise after FDA fast-track
06/20/16 03:49 PMFate Therapeutics Announces FDA Fast Track Designation for ProTmune™
06/20/16 12:22 PM10 Biggest Mid-Day Gainers For Monday -   Lpath, Inc. (NASDAQ: LPTN) shares jumped 58.17 percent to $3.29 as the company reported that it has been awarded a $1.45 million 2-year grant for traumatic brain injury pain study. Fate Therapeutics Inc (NASDAQ: FATE) gained 19.90 percent to $2.01 as the company reported the FDA Fast Track designation for ProTmune. Neovasc Inc (US) (NASDAQ: NVCN) shares surged 17.66 percent to $0.900 as the company reported that positive results for Reducer system treatment for refractory angina were published in The Netherlands Heart Journal. Cerus Corporation (NASDAQ: Full story available on Benzinga.com
06/20/16 10:09 AMFate Therapeutics to Host Off-the-Shelf Cancer Immunotherapy Focus Session at 2016 Annual Meeting of International ... - PharmiWeb.com (press release)
06/20/16 10:09 AMBRIEF-Fate Therapeutics announces FDA fast track designation for Protmune - Reuters
06/20/16 07:52 AM12 Stocks Moving In Monday's Pre-Market Session - Gainers Neovasc Inc (US) (NASDAQ: NVCN) shares rose 33.35 percent to $1.020 in pre-market trading as the company reported that positive results for Reducer system treatment for refractory angina were published in The Netherlands Heart Journal. Fate Therapeutics Inc (NASDAQ: FATE) rose 27.98 percent to $2.15 in pre-market trading as the company reported the FDA Fast Track designation for ProTmune. Cerus Corporation (NASDAQ: CERS) shares rose 13.16 percent to $6.45 in pre-market trading as the company announced an agreement Sunday with the BARDA for potential funding of up to $180 million to advance INTERCEPT red blood cell program. Clean Energy Fuels Corp (NASDAQ: CLNE) rose 9.01 ...Full story available on Benzinga.com
06/20/16 07:40 AMCould This Be a Turning Point for Fate Therapeutics? -

Social

About Fate Therapeutics

Fate Therapeutics logoFate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular therapeutics. The Company has a number of programmed cellular therapeutic candidates in development and research. The Company's development programs include ProHema (FT1050-modulated hematopoietic cells within umbilical cord blood (UCB)), which targets Hematologic, Malignancies and Inherited Metabolic Disorders therapeutic conditions and are in Phase II, Phase Ib and Phase Ib, respectively. Its development programs also include Programmed hematopoietic cells within mobilized peripheral blood (mPB) (FT1050+FT4145-modulated mPB), which is for Hematologic and Malignancies therapeutic area, and is in IND enablement-stage. Its research programs include Programmed Hematopoietic Cells, human induced pluripotent stem cells (hiPSC)-derived Hematopoietic Cells and hiPSC-derived Myogenic Progenitor Cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FATE
  • CUSIP:
Key Metrics:
  • Previous Close: $1.70
  • 50 Day Moving Average: $1.76
  • 200 Day Moving Average: $1.90
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $49.07M
  • Beta: 0.59
  • Current Year EPS Consensus Estimate: $-1.25 EPS
  • Next Year EPS Consensus Estimate: $-1.19 EPS
Additional Links:
Fate Therapeutics (NASDAQ:FATE) Chart for Sunday, July, 24, 2016